Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CBIO vs CAMP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CBIO Captures Overall Composite Edge (42.4 HOLD vs 43.9 HOLD), While CAMP Leads 4–1 on Growth & Valuation Pillars
CBIO Overall Winner
6-Pillar Tally: CBIO 1 – 4 CAMP (1 Tie)
Matrix Metrics: CBIO 2 – 4 CAMP
As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 2–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CBIO trades at $13.05 (N/M Forward P/E, -1228.4% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin).
- Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY).
- Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CBIO vs CAMP
CBIO
Head-to-Head Winner
Crescent Biopharma, Inc. Common Stock
$13.05
-3.3% 1D
Market Cap
$591.3M
TTM Revenue
$15M
Forward P/E
N/M
Beta / 30D Vol
1.37β · 58% Vol
Unified Composite Score
42.4
HOLD
Tech 36.0
Fund 51.0
Flow 65.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
CAMP
CAMP4 Therapeutics Corporation Common Stock
$4.00
+3.63% 1D
Market Cap
$238.5M
TTM Revenue
$5.3M
Forward P/E
N/M
Beta / 30D Vol
1.35β · 94% Vol
Unified Composite Score
43.9
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CBIO 1 – 4 CAMP)
1. Valuation Multiples
CAMP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
28.1x
26.6x
2. Growth & Scale
CAMP
Revenue Growth (YoY)
+0.0%
+138.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$15M
$5.3M
Market Cap
$591.3M
$238.5M
3. Profitability & Quality
CAMP
Gross Margin
100.0%
N/A
Operating Margin
-1228.4%
-991.8%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-160.8%
-146.1%
4. Balance Sheet & Cash Flow
CAMP
Cash Generation (TTM)
-$154M
-$26M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$170M Net Cash
$97M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CBIO
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
127.8% (10th %ile)
N/A (N/A)
Put/Call OI Skew
1.07x (Balanced)
N/A
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CBIO (2) vs CAMP (4)| Institutional Metric | CBIO | CAMP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $591.3M | $238.5M | CBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +138.9% | CAMP | |
| Operating Margin (TTM) | -1228.4% | -991.8% | CAMP | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -160.8% | -146.1% | CAMP | |
| 52-Week Range Position | 23% ($9–$27) | 23% ($3–$8) | Tie | |
| Beta / 30D Volatility | 1.37β · 58% Vol | 1.35β · 94% Vol | CBIO | |
| Unified Institutional Score | 42.4 / 100 (HOLD) | 43.9 / 100 (HOLD) | CAMP | |
| Trailing 12M Revenue (USD) | $15M | $5.3M | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 28.1x EV/Rev | N/M PEG · 26.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$154M ($170M Net Cash) | -$26M ($97M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAMP +21.77 pp
3M Horizon
CAMP +10.64 pp
6M Horizon
CAMP +25.75 pp
1Y Horizon
CBIO +2.71 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CBIO Revenue | CAMP Revenue | CBIO Op. Margin | CAMP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2015 | $20M | N/A | -63.7% | N/A | CBIO |
| FY2016 | $0M | N/A | -172505.3% | N/A | CBIO |
| FY2020 | $10M | N/A | -506.8% | N/A | CBIO |
| FY2021 | $0M | N/A | -5470.7% | N/A | CBIO |
| FY2022 | $0M | N/A | -63204.4% | N/A | CBIO |
| FY2023 | $0M | $0M | -392752.9% | -14822.6% | CAMP |
| FY2024 | N/A | $0M | N/A | -8142.3% | CAMP |
| FY2025 | $10M | $0M | -1407.5% | -1502.4% | CBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CBIO
BREAKDOWN
Current IV
127.8%
IV Percentile
10th %ile
Put/Call OI Skew
1.07x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAMP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CAMP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CBIO vs CAMP Key Questions & Quantitative Answers
As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 2–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CBIO trades at $13.05 (N/M Forward P/E, -1228.4% operating margin) versus CAMP at $4.00 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY). Technical & Structure Timing Caution: CBIO is currently in a Breakdown options structure phase (RSI 45.6); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: CBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), CBIO cumulative revenue shifted -50.0% while CAMP shifted N/A. In operating R&D and SG&A reinvestment, CBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.
CAMP screens cheaper on headline valuation multiples. CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 28.1x EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBIO (-160.8% ROE) versus CAMP (-146.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CBIO carries 127.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 58% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAMP vs CBIO · Reverse Pair
CBIO vs BNTC
· Sector Peer
CBIO vs AKTX
· Sector Peer
CAMP vs HLIT
· Sector Peer
CAMP vs ADTN
· Sector Peer
CAMP vs DGII
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem